Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years

Trial Profile

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs VLA 15 (Primary)
  • Indications Lyme disease
  • Focus Adverse reactions; First in man
  • Sponsors Valneva
  • Most Recent Events

    • 19 Mar 2018 Positive interim results for the primary and secondary endpoints including safety and immunogenicity data up to Day 84 (month 3) presented in the Valneva media release.
    • 18 Mar 2018 According to a Valneva media release, final safety and immunogenicity data including one year follow-up are expected early 2019.
    • 24 Jul 2017 According to a Valneva media release, the company expects to announce first results from the study in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top